Last reviewed · How we verify

NCT05620420

A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma

Completed Last updated 26 November 2024
What this trial tests

trial in Psychological Distress in 501 participants. Completed in 7 November 2023.

Timeline
8 November 2022
Primary endpoint
7 November 2023
7 November 2023

Quick facts

Lead sponsorRenJi Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment501
Start date8 November 2022
Primary completion7 November 2023
Estimated completion7 November 2023
Sites1 location across China

Conditions studied

Sponsor

RenJi Hospital

Who can join

18 and older, any sex, with Psychological Distress or Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma patients with normal ability of communication and understanding will be enrolled. DT, GAD-7, PHQ-15 and PSQI scales are designed to assess the mental health status of the patients. Demographic and disease data of patients will be collected as well. The main aim is to explore the factors affecting the mental health of myeloma patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Psychological Distress

Currently open trials in the same condition.

Other RenJi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05620420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing